Abstract:OBJECTIVE:The optimal treatment for primary non-Hodgkin's lymphoma (NHL) of the nasal cavity remains controversial. This study was to analyze the initial response rate of radiotherapy and chemotherapy, and the influence of different treatment modalities on prognosis.METHODS:From January 1996 to December 2002, the clinical data of 129 patients with previously untreated nasal NHL were retrospectively reviewed with all lesions confirmed by pathology. 116 patients were morphologically diagnosed as having nasal NK/T cell lymphoma. The immunophenotype was available in 57 cases and 52 (91.2%) of them were confirmed as NK/T-cell lymphoma. According to the Ann Arbor Staging System, 102 patients had stage I(E), 22 stage II(E), and 5 stage IV(E) disease. Among the 124 patients with stage I(E) and II(E) diseases, 22 patients received radiotherapy alone, 7 chemotherapy alone, and 95 combined modality therapy (CMT). Of these 95 patients treated with CMT, 45 patients were treated with radiotherapy followed by chemotherapy, and 50 with chemotherapy followed by radiotherapy. The primary treatment for stage IV(E) patients was chemotherapy with or without radiotherapy to the primary tumor.RESULTS:The overall 5-year survival (OS) and disease free survival (DFS) for all patients was 68.0% and 55.8%, respectively. It was 71.7% and 60.9% for stage I(E), and 70.6% and 47.0% for stage II(E), respectively (P > 0.05). The OS and DFS at the 5th year were 83.1% and 68.0% for patients who achieved complete response (CR), and 18.0% and 15.5% for those who did not, respectively (P = 0.000). Of the 124 patients with stage I(E) and II(E) disease, 67 patients were treated with radiotherapy alone (22 patients) or radiotherapy followed by chemotherapy (45), whereas 57 were treated with chemotherapy followed by radiotherapy (50) or chemotherapy alone (7). The CR rate after radiotherapy was 74.7%, however, it was only 19.3% after chemotherapy (P = 0.000). Of the 46 patients with PR, SD or PD after chemotherapy, 42 still had locoreginally localized lesion and 31 of these patients achieved CR by following radiotherapy which revealed satisfactory results. For stage I(E) and II(E) disease, the 5-year OS and DFS were 76.0% and 65.0% for radiotherapy with or without chemotherapy, and 74.4% and 56.2% for chemotherapy followed by radiotherapy. The difference was statistically not significant. However, 7 stage I(E) and II(E) patients were treated with chemotherapy alone, and 4 of them died of disease progression, with 1-year survival of 26.7%.CONCLUSION:The majority of Chinese patients with primary nasal NHL are NK/T cell in origin. The complete response rate by radiotherapy is much higher than that by chemotherapy. The addition of chemotherapy to radiotherapy did not improve the survival of patients with early stage nasal lymphoma. Radiotherapy is suggested as the primary treatment for stage I(E) and II(E) nasal NK/T cell lymphoma.

Early or Up-Front Radiotherapy Improved Survival of Localized Extranodal NK/T-Cell Lymphoma, Nasal-Type in the Upper Aerodigestive Tract

Patterns Of Local Extension And Regional Spread In Early Stage Nasal Nk/T-Cell Lymphoma Based On Magnetic Resonance Imaging

Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma.

Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell Lymphoma.

Radiotherapy is Essential after Complete Response to Asparaginase-Containing Chemotherapy in Early-Stage Extranodal Nasal-Type NK/T-cell Lymphoma: A Multicenter Study from the China Lymphoma Collaborative Group (CLCG).

[Outcome of Radiotherapy for Low-Risk Early-Stage Patients with Extranodal NK/T-cell Lymphoma, Nasal-Type].

Risk-adapted Therapy for Early-Stage Extranodal Nasal-Type NK/T-cell Lymphoma: Analysis from a Multicenter Study

Deep Remission from Induction Chemotherapy Predicts Favorable Long-Term Survivals in Early Stage Extranodal Nasal NK/T-cell Lymphoma Receiving Sequential Chemotherapy and Radiation.

Prognostic Factors and Treatment Outcomes for Patients with Stage II Extranodal Nasal-Type Natural Killer/t-Cell Lymphoma of the Upper Aerodigestive Tract

Mild Toxicity and Favorable Prognosis of High–Dose and Extended Involved-Field Intensity-Modulated Radiotherapy for Patients with Early-Stage Nasal NK/T-Cell Lymphoma

Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma

Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma

Treatment Outcomes and Prognostic Factors of Chemotherapy Combined with Radiation Therapy for Patients with Early-Stage Extranodal Natural Killer/T-Cell Lymphoma.

Risk‐based, response‐adapted therapy for early‐stage extranodal nasal‐type NK /T‐cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study

Efficacy and toxicities of chemoradiotherapy in the treatment of early stage extranodal nasal-type NK/T-cell lymphoma

Primary Radiotherapy Showed Favorable Outcome in Treating Extranodal Nasal-Type NK/T-cell Lymphoma in Children and Adolescents

The prognostic role of level of involved regional lymph node in patients with stage Ⅱ extranodal nasal-type NK/T-cell lymphoma of the upper aerodigestive tract

Neoadjuvant Chemotherapy And Prognostic Subgroups Defined By Survival Benefit In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma.

Survival benefit with salvage radiotherapy for patients with locoregionally recurrent extranodal NK/T cell lymphoma, nasal type

[Treatment Option and Outcome for Patients with Primary Non-Hodgkin's Lymphoma of the Nasal Cavity].

First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG